Compare Chewy Inc (CHWY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chewy Inc vs Novartis AG — how do they compare? Chewy Inc trades at $22.23 (market cap $9.20B), while Novartis AG trades at $152.76 (market cap $295.37B). The key difference: Novartis AG is far larger — about 32.1× Chewy Inc's market cap, and Novartis AG pays a 3.07% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.
| CHWY | NVS | |
|---|---|---|
Market Cap | $9.20B | $295.37B |
Sector | Consumer Cyclical | Health |
52-Week High | $42.33 | $168.62 |
52-Week Low | $17.51 | $119.31 |
Enterprise Value | $9.16B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chewy (CHWY) trades at $22.59, down 3.99% on the day, reflecting near-term bearish technical pressure. The stock shows strong fundamental progress with revenue climbing to $11.86B in 2025 and net income surging to $392.74M, marking a significant profitability turnaround. Recent earnings beats in Q3 2025 and Q1 2026 contrast with a Q4 2025 miss, indicating volatility. Analyst sentiment remains overwhelmingly positive with an 81.58% buy rating and a $33.82 consensus price target, suggesting substantial upside potential from current levels.
The investment outlook for CHWY is constructive, driven by robust revenue growth, expanding margins, and strong analyst conviction. Key opportunities include the company's dominant position in the pet care e-commerce space and its high customer loyalty through the Autoship subscription model. Primary risks involve competitive pressures from larger retailers, execution challenges in integrating veterinary services, and sensitivity to consumer spending trends. The stock presents a growth opportunity but requires monitoring of quarterly execution against high expectations.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
